Wet Age-related Macular Degeneration
📧 Sign up to get email alerts when something new happens for Wet Age-related Macular Degeneration.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-05-16Clinical Trial Update: Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial [Phase 1, Phase 2]
A phase 1/2 trial update reports safety and tolerability findings for RGX-314 gene therapy in neovascular age-related macular degeneration, …
-
CLINICAL_TRIALS trial_result · 2023-02-16Clinical Trial Update: This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMD [Phase 3]
A Phase 3 trial comparing SCT510A given by intravitreal injection to ranibizumab for wet age-related macular degeneration.
-
EMA withdrawal · 2022-12-02EMA Withdrawn: Macugen (pegaptanib) — PharmaSwiss Ceska Republika s.r.o
EMA has withdrawn Macugen (pegaptanib) for wet age-related macular degeneration.
-
CLINICAL_TRIALS withdrawal · 2022-08-10Clinical Trial Update: Brolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation [Phase 4]
A Phase 4 trial comparing brolucizumab vs. aflibercept for wet macular degeneration has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2022-06-14Clinical Trial Update: Treat and Extend Analysis Trial With Aflibercept in Wet-AMD [Phase 3]
A Phase 3 clinical trial update for treat-and-extend analysis with aflibercept in wet age-related macular degeneration.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA withdrawal · 2022-05-24EMA Refused: Ipique (bevacizumab) — Rotterdam Biologics B.V.
The EMA refused the marketing authorization for Ipique (bevacizumab) by Rotterdam Biologics B.V. for wet age-related macular degeneration.
-
CLINICAL_TRIALS trial_result · 2022-04-25Clinical Trial Update: A Study to Compare QL1207 to Eylea® in Subjects With Wet Age-related Macular Degeneration (wAMD) [Phase 3]
A Phase 3 trial comparing QL1207 to Eylea in wet age-related macular degeneration has completed.
-
CLINICAL_TRIALS trial_result · 2022-03-28Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMD [Phase 2, Phase 3]
A clinical trial update reports a study evaluating MW02 for wet age-related macular degeneration across Phase 2 and Phase 3.
-
FDA approval · 2022-02-18FDA Approved: BEOVU — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for BEOVU (brolucizumab) submitted by Novartis Pharmaceuticals Corporation.
-
CLINICAL_TRIALS trial_result · 2022-01-10Clinical Trial Update: Evaluation of RC28-E Injection in Wet Age-related Macular Degeneration [Phase 1, Phase 2]
A phase 1/2 trial evaluating RC28-E injection for wet age-related macular degeneration has been completed.
-
CLINICAL_TRIALS trial_result · 2022-01-06Clinical Trial Update: The IAI-OCTA Study; a Study of OCT-Angiography Analysis Efficacy [Phase 4]
Phase 4 trial update evaluating OCT-Angiography analysis efficacy for wet age-related macular degeneration.
-
FDA approval · 2021-10-22FDA Approved: SUSVIMO — Original Application (Genentech, Inc.)
FDA approved SUSVIMO, a port delivery system delivering ranibizumab, for the treatment of wet age-related macular degeneration.
-
CLINICAL_TRIALS trial_result · 2021-04-23Clinical Trial Update: A Study To Evaluate CKD-701 and Lucentis® in Patients With Neovascular(Wet) Age Related Macular Degeneration [Phase 3]
APhase 3 trial evaluating CKD-701 and Lucentis in neovascular (wet) age-related macular degeneration has completed.
-
CLINICAL_TRIALS trial_result · 2021-03-25Clinical Trial Update: EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection [Phase 4]
Phase 4 trial evaluating genotypes using intravitreal aflibercept in macular degeneration has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2020-10-06Clinical Trial Update: Ziv-aflibercept Efficacy in Better Regulating AMD [Phase 2]
Phase 2 trial update on ziv-aflibercept for wet macular degeneration shows efficacy signals in regulating disease.
-
CLINICAL_TRIALS trial_result · 2020-09-25Clinical Trial Update: The Study of Drug SCT510A in Patients With Wet Age-related Macular Degeneration (wAMD) [Phase 1, Phase 2]
Phase 1/2 study of SCT510A in wet age-related macular degeneration is listed with unknown status.
-
CLINICAL_TRIALS trial_result · 2020-08-28Clinical Trial Update: Evaluate the Therapeutic Effects and Safety of ALK4290 in Patients With Refractory Wet Age-Related Macular Degeneration [Phase 2]
Phase 2 clinical trial evaluating ALK4290 for wet age-related macular degeneration has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-08-28Clinical Trial Update: Evaluate the Effects and Safety of ALK4290 in Patients With Newly Diagnosed Wet Age-Related Macular Degeneration [Phase 2]
Phase 2 trial assessing ALK4290 for newly diagnosed wet age-related macular degeneration has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2019-10-23Clinical Trial Update: Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre) [Phase 4]
Phase 4 trial comparing intensive versus relaxed ranibizumab regimens for subfoveal choroidal neovascularization due to wet age-related macu…
-
FDA approval · 2019-08-12FDA Approved: EYLEA — Supplemental Application (Regeneron Pharmaceuticals, Inc.)
The FDA approved Regeneron's supplemental application for EYLEA (aflibercept), updating its labeling to reflect an expanded or modified indi…
-
CLINICAL_TRIALS trial_result · 2019-07-19Clinical Trial Update: Safety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye [Phase 4]
Phase 4 clinical trial update assessing safety and tolerability of ranibizumab in patients with wet age-related macular degeneration, includ…
-
CLINICAL_TRIALS trial_result · 2019-05-07Clinical Trial Update: Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration [Phase 4]
Phase 4 trial comparing systemic VEGF protein dynamics after intravitreal ranibizumab versus aflibercept in wet age-related macular degenera…
-
CLINICAL_TRIALS research · 2019-02-15Clinical Trial Update: To Describe the Use of Intravitreal Aflibercept and to Describe Follow-up as Well as Treatment Patterns in Patients With Wet Age-related Macular Degeneration (wAMD) or Diabetic Macular Edema (DME) in Routine Clinical Practice in Canada.
A clinical trial update describing real-world use of intravitreal aflibercept and follow-up/treatment patterns for wet age-related macular d…
-
CLINICAL_TRIALS trial_result · 2019-02-05Clinical Trial Update: Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept. [Phase 1, Phase 2]
This document reports the completion of Phase 1/2 clinical trials evaluating ranibizumab for recalcitrant wet age-related macular degenerati…
-
CLINICAL_TRIALS trial_result · 2018-11-23Clinical Trial Update: Study to Evaluate Efficacy of Aflibercept in Neovascular Age-related Macular Degeneration Patients Non Responders to Anti-Vascular Endothelial Growth Factor [Phase 4]
Phase 4 trial evaluating aflibercept in neovascular age-related macular degeneration patients who are non-responders to anti-VEGF therapy ha…